| __timestamp | Alpine Immune Sciences, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 2287709 | 14993000000 |
| Thursday, January 1, 2015 | 6844000 | 14247000000 |
| Friday, January 1, 2016 | 8586000 | 14192000000 |
| Sunday, January 1, 2017 | 6079000 | 14997000000 |
| Monday, January 1, 2018 | 8362000 | 16471000000 |
| Tuesday, January 1, 2019 | 9467000 | 14369000000 |
| Wednesday, January 1, 2020 | 10899000 | 14197000000 |
| Friday, January 1, 2021 | 14560000 | 14886000000 |
| Saturday, January 1, 2022 | 17968000 | 14253000000 |
| Sunday, January 1, 2023 | 22222000 | 12489000000 |
| Monday, January 1, 2024 | 12566000000 |
Igniting the spark of knowledge
In the world of pharmaceuticals and biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Novartis AG, a global healthcare giant, and Alpine Immune Sciences, Inc., a burgeoning biotech firm, have showcased contrasting SG&A spending patterns.
From 2014 to 2023, Novartis AG consistently allocated a significant portion of its budget to SG&A, peaking in 2018 with expenditures reaching approximately $16.5 billion. This reflects a strategic focus on maintaining its market dominance. In contrast, Alpine Immune Sciences, Inc. demonstrated a steady increase in SG&A spending, culminating in a 2023 peak of around $22 million, a nearly tenfold increase from 2014. This growth underscores Alpine's aggressive expansion strategy in a competitive market.
These spending patterns highlight the diverse strategies employed by established and emerging players in the industry.
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Comparing SG&A Expenses: Novartis AG vs Cytokinetics, Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Novartis AG and Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Alpine Immune Sciences, Inc.
Who Optimizes SG&A Costs Better? United Therapeutics Corporation or Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Alpine Immune Sciences, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Alpine Immune Sciences, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and ACADIA Pharmaceuticals Inc.